Want to see ELAN full AI Analyst Report?
ELAN Stock Chart & Stats
$25.08
$0.50(2.01%)
At close: 4:00 PM EDT
$25.08
$0.50(2.01%)
Day’s Range― - ―
52-Week Range$19.40 - $27.98
Previous CloseN/A
Volume2.71M
Average Volume (3M)5.46M
Market Cap
$11.25B
Enterprise Value$15.84B
Total Cash (Recent Filing)$530.00M
Total Debt (Recent Filing)$3.92B
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Nov 06, 2026EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding499,621,830
10 Day Avg. Volume4,785,841
30 Day Avg. Volume5,462,162
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.72
Price to Sales (P/S)2.38
P/FCF Ratio39.55
Enterprise Value/Market Cap1.41
Enterprise Value/Revenue3.16
Enterprise Value/Gross Profit6.00
Enterprise Value/Ebitda20.46
Forecast
1Y Price Target
$31.00Price Target Upside23.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)1.14
Revenue Forecast (FY)$5.14B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthBroad-based organic growth and raised full-year guidance indicate improving demand across Elanco’s portfolio. Continued volume and pricing contributions can support durable revenue expansion, strengthen operating leverage, and provide a foundation for funding innovation and debt reduction.
Innovation And Product AdoptionThe expanding innovation portfolio provides a durable growth engine beyond legacy products. Strong adoption, clinic penetration, and reorder activity for newer brands suggest meaningful customer acceptance, supporting future revenue mix improvement and competitive relevance.
Cash Generation And DeleveragingPositive free cash flow despite negative net income gives Elanco capacity to service debt, reinvest in launches, and improve financial flexibility. Combined with declining leverage, this cash generation supports a more resilient balance sheet over the next several quarters.
Bears Say
Persistent Net LossesRevenue and gross-margin gains have not yet produced consistent bottom-line profitability. Persistent net losses and negative returns on equity reduce the company’s ability to compound capital efficiently and leave execution improvements necessary before earnings quality can be considered durable.
Meaningful LeverageLeverage has improved, but a 3.1x net leverage level still limits financial flexibility relative to a lightly indebted business. Debt obligations can constrain capital allocation and increase sensitivity to weaker operating performance while management works toward its longer-term 2.0x-2.5x target.
Befrena Supply ConstraintsDemand exceeding expectations is positive, but prolonged supply constraints can delay revenue capture from a strategically important new launch. The extended bioreactor-scaling timeline may limit near-term commercial momentum and increase execution pressure as Elanco expands the product.
ELAN FAQ
What was Elanco Animal Health’s price range in the past 12 months?
Elanco Animal Health lowest stock price was $19.40 and its highest was $27.98 in the past 12 months.
What is Elanco Animal Health’s market cap?
Elanco Animal Health’s market cap is $11.25B.
When is Elanco Animal Health’s upcoming earnings report date?
Elanco Animal Health’s upcoming earnings report date is Nov 06, 2026 which is in 13 days.
How were Elanco Animal Health’s earnings last quarter?
Elanco Animal Health released its earnings results on Aug 05, 2026. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.269 by $0.071.
Is Elanco Animal Health overvalued?
According to Wall Street analysts Elanco Animal Health’s price is currently Undervalued.
Does Elanco Animal Health pay dividends?
Elanco Animal Health does not currently pay dividends.
What is Elanco Animal Health’s EPS estimate?
Elanco Animal Health’s EPS estimate is 0.21.
How many shares outstanding does Elanco Animal Health have?
Elanco Animal Health has 499,621,830 shares outstanding.
What happened to Elanco Animal Health’s price movement after its last earnings report?
Elanco Animal Health reported an EPS of $0.34 in its last earnings report, beating expectations of $0.269. Following the earnings report the stock price went up 2.422%.
Which hedge fund is a major shareholder of Elanco Animal Health?
Currently, no hedge funds are holding shares in ELAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elanco Animal Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.00 (23.60% Upside)
$31.00 (23.60% Upside)
Blogger Sentiment
Neutral
ELAN Sentiment 57%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 247.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $537.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.85%
12-Months-Change
Fundamentals
Return on Equity
-3.02%
Trailing 12-Months
Asset Growth
-1.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Elanco Animal Health
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
ELAN Company Deck
ELAN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: strong top-line performance (8% organic growth, $1.368B revenue), robust innovation momentum (Zenrelia, Credelio Quattro, AdTab), margin expansion (adjusted gross margin +80 bps, adjusted EBITDA +21%, adjusted EPS +31%), raised full-year guidance, and improving leverage (target ~3.0x year-end). Near-term headwinds include inventory cost pressures, elevated inflation, continued operating expense investments (DTC/R&D) and some regional/timing softness in International Farm Animal. Supply constraints for Befrena and moderating comparisons for some Farm Animal products are acknowledged but framed as manageable. Overall, highlights materially outweigh the limited lowlights.View all ELAN earnings summariesELAN Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$31.00
▲(23.60% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
1.01% Insiders
51.31% Mutual Funds
2.10% Other Institutional Investors
20.91% Public Companies and
Individual Investors









